1. Home
  2. LTBR vs DRTS Comparison

LTBR vs DRTS Comparison

Compare LTBR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$10.72

Market Cap

575.6M

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$6.85

Market Cap

546.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
DRTS
Founded
1992
2015
Country
United States
Israel
Employees
N/A
125
Industry
Professional Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
575.6M
546.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
LTBR
DRTS
Price
$10.72
$6.85
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
776.0K
227.4K
Earning Date
05-11-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$965.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.10
$2.30
52 Week High
$31.34
$8.60

Technical Indicators

Market Signals
Indicator
LTBR
DRTS
Relative Strength Index (RSI) 38.08 45.05
Support Level N/A $6.37
Resistance Level $15.48 $7.75
Average True Range (ATR) 0.61 0.42
MACD 0.06 -0.04
Stochastic Oscillator 28.57 25.00

Price Performance

Historical Comparison
LTBR
DRTS

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Share on Social Networks: